Libtayo and Cough - a phase IV clinical study of FDA data

Summary:

Cough is reported as a side effect among people who take Libtayo (cemiplimab-rwlc), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Ondansetron, and have High blood pressure.

The phase IV clinical study analyzes which people have Cough when taking Libtayo. It is created by eHealthMe based on reports of 1,159 people who have side effects when taking Libtayo from the FDA, and is updated regularly.

What is Libtayo?

Libtayo has active ingredients of cemiplimab-rwlc. eHealthMe is studying from 1,161 Libtayo users. Check the latest studies of Libtayo.

What is Cough?

Cough is found to be associated with 3,058 drugs and 3,798 conditions by eHealthMe. Check the latest studies of Cough.

On May, 14, 2026

1,159 people reported to have side effects when taking Libtayo.
Among them, 16 people (1.38%) have Cough.

Among these 16 people:

* Approximation only. Some reports may have incomplete information.

Do you take Libtayo and have Cough?

- Check whether Cough is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Libtayo:

Libtayo (1,161 reports)

Cough treatments and more:

Cough (361,787 reports)

How severe was Cough and when was it recovered:

Cough in Libtayo

Expand to all the drugs that have ingredients of cemiplimab-rwlc:

Cough and drugs with ingredients of cemiplimab-rwlc

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Libtayo:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Cough:

Cough (3,058 drugs)

Browse all the conditions that are associated with Cough:

Cough (3,798 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on cemiplimab-rwlc (the active ingredients of Libtayo) and Libtayo (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.